Theratechnologies Announces Renewal of Shelf Prospectus and Registration Statement; At-The-Market Facility to be Extended
MONTREAL, Nov. 23, 2021 /CNW Telbec/ - Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has filed a preliminary short form base shelf prospectus with the securities regulatory authorities of all the provinces of Canada and a corresponding shelf registration statement with the United States Securities and Exchange Commission (the "SEC") on Form F-10.
The filing is made for the purpose of restoring the original financing capacity which was available to Theratechnologies under its previous base shelf prospectus dated November 15, 2019 expiring on December 15, 2021.
Once the shelf prospectus is cleared and the shelf registration statement becomes effective, these filings will, subject to securities regulatory requirements, provide for the potential offering in Canada and the United States of up to an aggregate of US $150,000,000 of common shares, preferred shares, subscription receipts, warrants, debt securities and units from time to time over a 25-month period after Canadian securities regulatory authorities have issued a receipt for the final short form base shelf prospectus. This shelf prospectus is intended to give the Company the flexibility to take advantage of financing opportunities when market conditions are favourable. The terms of such future offerings, if any, will be established at the time of such offerings. At the time any of the securities covered by the shelf prospectus are offered for sale, a prospectus supplement containing specific information about the terms of any such offering will be filed with applicable Canadian securities regulatory authorities and the SEC.
The shelf registration statement filed with the SEC has not yet become effective. No securities may be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any offer, solicitation or sale of, securities in any province, state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.
Renewal of ATM Facility
Upon the short form base shelf prospectus and shelf registration statement becoming effective, the Company also intends to file a prospectus supplement to the shelf registration statement to renew its prospectus supplement of July 23, 2021 relating to its US $50,000,000 at-the-market ("ATM") facility, which the Company intends on extending for the duration of up to 25 months following the receipt of the Canadian securities regulatory authorities for the base shelf prospectus. The Company expects that the ATM sales agreement will be extended in respect of the renewed prospectus supplement and corresponding shelf registration statement.
A copy of the preliminary base shelf prospectus and corresponding shelf registration statement is available on our SEDAR profile at www.sedar.com or on EDGAR at www.sec.gov. Alternatively, a copy of such documents is available upon request by contacting the Company's Corporate Secretary at 2015 Peel Street, Suite 1100, Montreal, Qubec, Canada, H3A 1T8, telephone: (514) 336-7800.
About Theratechnologies
Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Further information about Theratechnologies is available on the Company's website at www.theratech.com, on SEDAR at www.sedar.com and on EDGAR at www.sec.gov.
Forward-Looking Information